4.5 Article

Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

M. A. Socinski et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer

L. Paz-Ares et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Article Oncology

Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer A Meta-Analysis

Chee Khoon Lee et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

Article Oncology

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

Jennifer H. Yearley et al.

CLINICAL CANCER RESEARCH (2017)

Article Medicine, General & Internal

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Martin Reck et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Review Oncology

Classifying Cancers Based on T-cell Infiltration and PD-L1

Michele W. L. Teng et al.

CANCER RESEARCH (2015)

Article Medicine, General & Internal

Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer

Edward B. Garon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Julie Brahmer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

H. Borghaei et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Oncology

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

Jacques Ferlay et al.

INTERNATIONAL JOURNAL OF CANCER (2015)

Article Medicine, Research & Experimental

Programmed death ligand-1 expression in non-small cell lung cancer

Vamsidhar Velcheti et al.

LABORATORY INVESTIGATION (2014)

Article Oncology

Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

Justin F. Gainor et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Review Immunology

Programmed Death Ligand 2 in Cancer-Induced Immune Suppression

Esdy N. Rozali et al.

CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)

Article Medicine, General & Internal

Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.

Makoto Maemondo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

Article Medicine, General & Internal

Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.

Tony S. Mok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)